Artificial intelligence startup PathAI announced the completion of $11 million in Series A financing led by General Catalyst Partners, with participation from Refactor Capital, 8VC, Danhua Capital, KdT Ventures, and Pillar.
PathAI’s intelligent pathology platform provides end-to-end, data-driven pathology analysis, resulting in fast, accurate, and standardized pathologic diagnoses. The company’s deep-learning solutions strive to accelerate R&D efforts and brings standardization to all phases of the drug development pipeline.
The startup will use the funds to build out its team and develop its artificial intelligence-based technology.
PathAI Brings In $11 Million
